Choroid Plexus Abnormalities in Autoimmune Encephalitis
CNS Neuroscience & Therapeutics · 2026-09 · 32 (9)
DOI: 10.1002/cns.71048 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 10.09.2026. Verfasst von Yueqian Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Choroid Plexus, Encephalitis, Hashimoto Disease. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Capital Health Research and Development of Special grants, National Key R&D Program of China grant.
Abstract (Originalsprache)
Background
Recent evidence suggests that the choroid plexus (ChP) serves as a gateway for neuroinflammation. Autoimmune encephalitis (AE) features a high inflammatory burden, yet the role of ChP in AE remains unclear. This study compared choroid plexus volume (CPV) at symptom onset between AE patients and healthy controls (HCs), and evaluated its association with prognosis.
Methods
This single‐center study included 151 AE patients with definite autoantibodies. ChP volume (CPV) was segmented from baseline 3D‐T1 MRI and normalized. Baseline CPV was compared between AE and age‐ and sex‐matched HCs, and its associations with 12‐month functional outcomes (mRS) and progression to autoimmune encephalitis‐associated epilepsy (AEAE) were assessed. A logistic regression model based on ChP radiomic features was developed to predict AEAE. Exploratory cerebrospinal fluid (CSF) proteomics and metabolomics were performed in a small subset to generate hypotheses on underlying pathways.
Results
Of 151 AE patients, 141 completed 12‐month follow‐up; 26 (18.4%) developed AEAE. AE patients had significantly larger CPV than controls (1.235 ± 0.274 vs. 1.035 ± 0.264, p < 0.001). Larger baseline CPV was significantly associated with AEAE and mRS ( p < 0.05). A two‐feature radiomic model (RunEntropy and original volume) predicted AEAE with AUCs of 0.766 (training) and 0.851 (test). Exploratory proteomics in a subset suggested CPV‐correlated downregulation of glutamatergic synapse pathways and upregulation of PI3K‐Akt/integrin pathways.
Conclusions
Baseline CPV was greater in AE patients than in HCs, and larger baseline CPV was associated with progression to AEAE and poor one‐year functional outcomes. ChP imaging may aid in early risk stratification for AE patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- National Center for Clinical Medicine of Neurological Diseases, Beijing, China.
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
- Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Yueqian Sun, Li Feng
Förderung
- National Natural Science Foundation of China
- Capital Health Research and Development of Special grants
- National Key R&D Program of China grant
- China Postdoctoral Science Foundation
- Beijing Postdoctoral Science Foundation
- CAAE Epilepsy Care Fund
Zitieren
APA
Sun, Y., Wang, N., Ge, S., Feng, L., & Wang, Q. (2026). Choroid Plexus Abnormalities in Autoimmune Encephalitis. CNS Neuroscience & Therapeutics, 32(9). https://doi.org/10.1002/cns.71048
Vancouver
Sun Y, Wang N, Ge S, Feng L, Wang Q. Choroid Plexus Abnormalities in Autoimmune Encephalitis. CNS Neuroscience & Therapeutics. 2026;32(9). doi:10.1002/cns.71048
BibTeX
@article{Sun2026,
author = {Sun, Yueqian and Wang, Ning and Ge, Shihao and Feng, Li and Wang, Qun},
title = {Choroid Plexus Abnormalities in Autoimmune Encephalitis},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {9},
doi = {10.1002/cns.71048}
}
EUVIMED